Literature DB >> 26107793

Managing nonteratogenic adverse reactions to isotretinoin treatment for acne vulgaris.

Bridget K Reilly1, Tamara S Ritsema.   

Abstract

Isotretinoin is the strongest, most effective oral treatment for patients with severe acne vulgaris, with remission rates of 89% and higher. Because of its potency, isotretinoin causes many adverse reactions. This article reviews common and severe adverse reactions to isotretinoin and how providers can best manage these reactions. Because of inconclusive research on the correlation between isotretinoin and depression and irritable bowel syndrome, providers should ask patients about symptoms monthly. Prescribing micronized isotretinoin and starting at the lowest dose with gradual upward titration also can help reduce the incidence of adverse reactions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26107793     DOI: 10.1097/01.JAA.0000459815.24908.02

Source DB:  PubMed          Journal:  JAAPA        ISSN: 0893-7400


  3 in total

1.  Efficacy and Tolerability of a Combined 445nm and 630nm Over-the-counter Light Therapy Mask with and without Topical Salicylic Acid versus Topical Benzoyl Peroxide for the Treatment of Mild-to-moderate Acne Vulgaris.

Authors:  Mark S Nestor; Nicole Swenson; Angela Macri; Mitchell Manway; Paige Paparone
Journal:  J Clin Aesthet Dermatol       Date:  2016-03-01

2.  Action of Mangifera indica Leaf Extract on Acne-Prone Skin through Sebum Harmonization and Targeting C. acnes.

Authors:  Morgane De Tollenaere; Cloé Boira; Emilie Chapuis; Laura Lapierre; Cyrille Jarrin; Patrick Robe; Catherine Zanchetta; David Vilanova; Bénédicte Sennelier-Portet; Jessy Martinez; Amandine Scandolera; Daniel Auriol; Romain Reynaud
Journal:  Molecules       Date:  2022-07-26       Impact factor: 4.927

3.  Efficacy of a New Non-drug Acne Therapy: Aloe Vera Gel Combined With Ultrasound and Soft Mask for the Treatment of Mild to Severe Facial Acne.

Authors:  Hongyu Zhong; Xiang Li; Wanqi Zhang; Xiaoxiao Shen; Yuangang Lu; Hongli Li
Journal:  Front Med (Lausanne)       Date:  2021-05-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.